Australia markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6600+0.0400 (+1.53%)
At close: 04:00PM EDT
2.7300 +0.07 (+2.63%)
After hours: 07:52PM EDT

Allakos Inc.

975 Island Drive
Suite 201
Redwood City, CA 94065
United States
650 597 5002
https://www.allakos.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 192

Key executives

NameTitlePayExercisedYear born
Dr. Robert Alexander Ph.D.CEO & Director1.39M15.59M1970
Dr. Adam L. Tomasi Ph.D.Pres & COO1.06M28.42M1970
Mr. Baird Radford IIIChief Financial Officer484.56kN/AN/A
Mr. Mark Asbury J.D.Exec. Officer701.69kN/A1963
Dr. Ruby Casareno Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Meg FitzgeraldSr. VP, Gen. Counsel, Sec. and Chief Compliance OfficerN/AN/AN/A
Dr. Sally D. BolmerSr. VP of Regulatory Affairs & Drug Devel.N/AN/AN/A
Dr. Henrik Sandvad RasmussenStrategic AdvisorN/AN/A1959
Dr. Craig Paterson M.D.Chief Medical OfficerN/AN/AN/A
Brad YoungbloodHead of ResearchN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Corporate governance

Allakos Inc.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.